The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
David Wise
Stock and Other Ownership Interests - Doximity
Honoraria - OncLive
Consulting or Advisory Role - Accutar Biotech; Alphasights; AstraZeneca; Bayer; Gerson Lehrman Group; Guidepoint Global; K36; Leap Therapeutics; OncoC4; Pfizer; silverlight
Travel, Accommodations, Expenses - Bayer; Bayer; Pfizer
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; Mashup Media; MJH Life Sciences; Peerview
Consulting or Advisory Role - Aravive; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Sanofi/Aventis; Seagen; Xencor
Research Funding - ALX Oncology (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Janux Therapeutics (Inst); Loxo/Lilly (Inst); OncoC4; Pfizer (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Bayer
Other Relationship - ASCO; Kidney Cancer Association; KidneyCan; Myrovlytis Trust; Winn Foundation
 
Ronald Tutrone
Employment - Chesapeake Urology
Stock and Other Ownership Interests - Compass Therapeutics; GlaxoSmithKline; ImmnityBio; Novartis; Urogen pharma; Veru
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences; Novartis; Nymox
Speakers' Bureau - Medivation/Astellas; Pfizer
Research Funding - Advantagene (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Blue Earth Diagnostics (Inst); Dendreon (Inst); ESSA (Inst); Exosome Diagnostics (Inst); Francis Medical (Inst); Genomic Health (Inst); Janssen Oncology (Inst); Lantheus Medical Imaging (Inst); Lilly (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); POINT Biopharma (Inst); Propella Therapeutics (Inst)
 
Biren Saraiya
Research Funding - Hookipa Pharma (Inst); Merck (Inst); OncoC4 (Inst); Regeneron (Inst)
 
Andrew Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Cytogen; Exelixis; GoodRx; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Alexandra Sokolova
No Relationships to Disclose
 
Shuchi Gulati
Honoraria - ASCO; Horizon CME; MashupMedia; Meetings, Events and Conference Coordinators Inc.
Consulting or Advisory Role - AVEO; EMD Serono; Puma Biotechnology
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Patent pending for: "Diagnostic tools for prediction of survival and responsiveness to treatments.” US17327100.
Travel, Accommodations, Expenses - ASCO; Conquer Cancer Foundation; Horizon CME; Meetings, Events and Conference Coordinators Inc.
 
Jose Avitia
No Relationships to Disclose
 
Manojkumar Bupathi
Honoraria - Agendia; AIQ Solutions; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Janssen; Myovant Sciences; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Pfizer
 
Svetlana Shpyro
Employment - BioNTech
 
Qiong Wang
Employment - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Travel, Accommodations, Expenses - BioNTech SE
 
Yang Liu
Employment - OncoC4
Leadership - OncoC4
Stock and Other Ownership Interests - OncoC4
Patents, Royalties, Other Intellectual Property - OncoC4
 
Pan Zheng
Employment - OncoC4
Leadership - OncoC4
Stock and Other Ownership Interests - OncoC4
Patents, Royalties, Other Intellectual Property - Patent on ONC-392, a new next generation anti-CTLA-4 antibody.
 
Mark Stein
Stock and Other Ownership Interests - Rafael Holdings
Consulting or Advisory Role - Bicycle Therapeutics (Inst); Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Regeneron (Inst); Repare Therapeutics (Inst); Vaccitech; Xencor
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals; Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Regeneron (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)